安大略省拒绝为有效的失眠药物提供公共资金,尽管已证明有益处,但仍限制人们获得药物。 Ontario denies public funding for effective insomnia drugs, limiting access despite proven benefits.

慢性失眠影响着成千上万的安大略人,特别是在监狱等高压环境中,心理健康恶化,侵害行为不断增加。 Chronic insomnia impacts thousands of Ontarians, especially in high-stress settings like prisons, worsening mental health and increasing aggression. 虽然在日本和德国等国家,称为DORA的更新、更安全的药物是有效的、广泛覆盖的,但安大略的公共药物计划没有覆盖这些药物,延缓了病人获得药物的机会。 Though newer, safer drugs called DORAs are effective and widely covered in countries like Japan and Germany, Ontario’s public drug plan does not cover them, delaying access for patients. 加拿大的药物机构建议将DORA排除在公共福利之外,从而建立了一个两级制度,只有那些拥有私人保险的人才能享受现代治疗。 Canada’s drug agency recommended excluding DORAs from public benefits, creating a two-tier system where only those with private insurance can access modern treatments. 大多数省只资助经批准的精神病药物的四分之一,平均延迟2.5年。 Most provinces fund only a quarter of approved psychiatric drugs, with an average 2.5-year delay. 专家说,将DORAs纳入安大略省的计划将改善健康成果,减少残疾,促进劳动力参与,降低长期成本,符合全球最佳做法。 Experts say including DORAs in Ontario’s plan would improve health outcomes, reduce disability, boost workforce participation, and lower long-term costs, aligning with global best practices.